

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday, 22 February 2017, 10am to 5pm

Venue: National Institute for Health and Care Excellence
10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler	Present for all notes
	2. Dr Ray Armstrong	Present for all notes
	3. Professor John Cairns	Present for all notes
	4. Mr Mark Chapman	Present for all notes
	5. Dr Sumeet Gupta	Present for all notes
	6. Dr Sanjay Kinra	Present for all notes
	7. Dr Miriam McCarthy	Present for all notes
	8. Mr Christopher O'Regan	Present for notes 1 to 19
	9. Dr Sanjeev Patel	Present for all notes
	10. Dr Danielle Preedy	Present for all notes
	11. Professor Ken Stein	Present for all notes
	12. Dr Nicky Welton	Present for all notes
	13. Mr Nigel Westwood	Present for all notes
	14. Dr Stuart Williams	Present for all notes

In attendance:

Bashama Anjum	Administrator, National Institute for Health and Care Excellence	Present for all notes
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Ahmed Elsada	Technical Advisor, Technology Appraisals, NICE	Present for notes 1 to 19
Liv Gualda	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Melinda Goodell	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jasdeep Hayre	Technical Adviser, National Institute for Health and Clinical	Present for notes 19 to 32

Excellence

Jessica Maloney	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 19
Thomas Strong	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 19 to 32
Irina Voicechovskaja	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 19 to 32
Mariana Bacelar	Evidence Review Group, Senior Health Economist, BMJ Evidence	Present for notes 1 to 19
Samantha Barton	Evidence Review Group, Evidence team lead BMJ Evidence	Present for notes 1 to 19
Steve Edwards	Evidence Review Group, Head of Health BMJ Evidence	Present for notes 1 to 19
Mark Rodgers	Evidence Review Group, Research Fellow, Centre for Reviews and Dissemination University of York	Present for notes 19 to 32
Claire Rothery	Evidence Review Group, Senior Research Fellow, Centre for Reviews and Dissemination University of York	Present for notes 19 to 32
Dr John Ashcroft	Consultant Haematologist, Mid Yorkshire NHS Trust/Leeds Teaching Hospitals NHS Trust, nominated by UK Myeloma Forum	Present for notes 1 to 19
David Chandler	Patient expert, Chief Executive, Psoriasis and Psoriatic Arthritis Alliance	Present for notes 19 to 32
Dr Karolina Gholam	Consultant Paediatric Dermatologist, Great Ormond Street Hospital, nominated by AbbVie	Present for notes 19 to 32
Eric Low	Chief Executive Myeloma UK, nominated by Myeloma UK	Present for notes 1 to 19
Barry Neville	Patient expert, nominated by Myeloma UK	Present for notes 1 to 19
Dr Cathy Williams	Consultant	Present for notes 1 to 19

Haematologist, Centre
for Clinical Haematology,
Nottingham University
Hospitals, nominated by
Janssen

Non-public observers:

Helen Barnett	Senior Medical Editor, NICE	Present for all notes
Luke Cowie	Scientific Adviser - Patient Preferences, NICE	Present for all notes
Heidi Livingstone	Senior Public Involvement Advisor, Communications, NICE	Present for all notes
Joshua South	Coordinator, National Institute for Health and Clinical Excellence	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933] and adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].
2. The Chair welcomed Dr Stuart Williams to their first meeting as a member of the Appraisal Committee.
3. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Heidi Livingstone and Luke Cowie.
4. Apologies were received from Dr Mark Glover, Mrs Anne Joshua, Dr Neil Losson, and Dr Nigel De Kare Silver.

Any other Business

5. None

Notes from the last meeting

6. Minutes from November, 2016 and January 2017 committee meetings were presented to the committee.

Appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933]

Part 1 – Open session

7. The Chair welcomed the invited experts: Dr John Ashcroft, Mariana Bacelar, Samantha Barton, Steve Edwards, Eric Low, Barry Neville, Dr Cathy Williams to the meeting and they introduced themselves to the Committee.
8. The Chair welcomed company representatives from Janssen to the meeting.
9. The Chair asked all Committee members to declare any relevant interests
 - 9.1. Dr Amanda Adler, Dr Ray Armstrong, Professor John Cairns, Mr Mark Chapman, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Dr Danielle Preedy, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].
10. The Chair asked all NICE Staff to declare any relevant interests.

- 10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].
11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].
12. The Chair introduced the lead team, Professor John Cairns, Dr Sumeet Gupta, and Dr Danielle Preedy who gave presentations on the clinical effectiveness and cost effectiveness of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.
17. The Committee continued to discuss the clinical and cost effectiveness of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].
18. The committee decision was based on consensus.
19. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

Part 1 – Open session

20. The Chair welcomed the invited expert: David Chandler and Dr Karolina Gholam to the meeting and they introduced themselves to the Committee.
21. The Chair welcomed company representatives from AbbVie to the meeting.
22. The Chair asked all Committee members to declare any relevant interests

Dr Amanda Adler, Dr Ray Armstrong, Professor John Cairns, Mr Mark Chapman, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Dr Sanjeev Patel, Dr Danielle Preedy, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

- 22.1. Christopher O'Regan declared a personal specific financial interest as his team had produced the assessment report for this appraisal, which he was directly involved.
9.3.1 It was agreed that this declaration would prevent Christopher O'Regan from participating in this section of the meeting.

23. The Chair asked all NICE Staff to declare any relevant interests.

- 23.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

24. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

- 24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

25. The Chair introduced the lead team, Dr Sanjay Kinra and Dr Miriam McCarthy, Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].
26. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

27. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
28. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

29. Discussion on confidential information continued. This information was supplied by the company.
30. The Committee continued to discuss the clinical and cost effectiveness of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].
31. The committee decision was based on consensus.
32. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

Thursday, 23 March 2017, 10am to 5pm at ETC venues, Prospero House, 241 Borough High Street, London SE1 1GA.